| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,885 |
3,162 |
$246K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,888 |
1,672 |
$85K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
273 |
269 |
$24K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
204 |
203 |
$17K |
| 92552 |
|
1,071 |
1,036 |
$14K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
695 |
663 |
$9K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
257 |
237 |
$7K |
| 87428 |
|
96 |
95 |
$4K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
182 |
170 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
162 |
134 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
588 |
508 |
$3K |
| 99173 |
|
1,170 |
1,132 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
214 |
104 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
30 |
30 |
$1K |
| 99050 |
|
134 |
126 |
$951.11 |
| 90686 |
|
109 |
107 |
$931.85 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
163 |
163 |
$753.57 |
| 96127 |
|
35 |
28 |
$76.54 |
| 99000 |
|
804 |
724 |
$36.47 |
| 99072 |
|
84 |
78 |
$0.00 |